SpringWorks Therapeutics, Inc.’s SWTX share price has surged by 11.08%, which has investors questioning if this is right time to sell.

Teacher Retirement System of Texas increased its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 26.4% ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of SpringWorks Therapeutics Inc (Symbol: SWTX) entered into oversold territory, hitting an RSI ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw unusually large options trading activity on Friday. Traders acquired 12,381 call options on the stock. This represents an increase of ...

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Unfortunately for shareholders, while the SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) share price is up 55% in the last five years, that's less than the market return. Zooming in, the stock is up ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The FDA has approved SpringWorks Therapeutics’s mirdametinib (Gomekli) for adult and paediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic ...

SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo’s revenues alone reached $172 million in 2024, supported by ...